Auxo Firm Directory · Independent Research Profile

Geller Biopharm Inc

Geller Biopharm Inc. is publicly described as a New York healthcare investment bank focused on biotechnology, biopharmaceutical, pharmaceutical, and medical-device companies. Its stated work includes licensing, mergers and acquisitions, advisory assignments, consulting, and financial raises.

Key takeaway

Public sources describe Geller Biopharm Inc.

as a healthcare investment-banking and advisory business serving life-sciences companies. Publicly identifiable work includes offerings, licensing, financing, consulting, and M&A-related assignments. Current engagement entity, firm-level registration status, fees, minimum criteria, and recent completed transactions should be confirmed directly.[1][2][3][4][13][14][15]

What does Geller Biopharm Inc do?

Geller Biopharm Inc. is publicly identified as a healthcare investment bank headquartered in New York, New York. Matthew Geller is identified as its founder, and the business was founded in 2008.

Current public materials connect Matthew Geller with Pickwick Capital Partners, where he is identified as a FINRA-registered representative. Historical SEC-filed materials describe Geller Biopharm as a healthcare investment-banking division of Financial West Group.[1][2][10]

Public descriptions associate Geller Biopharm with healthcare investment banking, licensing, mergers and acquisitions, advisory work, financial raises, and consulting. An attributed transaction announcement specifically describes assignments for biotechnology, pharmaceutical, and medical-device companies.

An SEC-filed issuer biography describes work involving advisory relationships, mergers, acquisitions, and sales of biotechnology companies. Pickwick’s current investment-banking page describes advisory and capital-raising services, but does not publish Geller Biopharm-specific fee schedules, minimum transaction criteria, or engagement terms.[1][3][4][14]

Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.

Public size / criteria information
The LinkedIn company page reports Geller Biopharm as privately held with 11-50 employees. The accessible Pickwick investment-banking page does not publish Geller Biopharm-specific minimum transaction criteria.[1]

What should a business owner evaluate before hiring Geller Biopharm Inc?

For an owner evaluating a sale, licensing transaction, strategic financing, or other capital-markets event in biotechnology or biopharmaceuticals, Geller Biopharm’s public record shows healthcare-sector experience across advisory, M&A, licensing, consulting, and financing-related work.

Before engagement, an owner should confirm which legal entity would sign the engagement and receive fees, the applicable registration and supervisory structure, fee and reimbursement provisions, exclusivity and termination terms, conflicts, active buyer or capital-source relationships, and recent completed healthcare transactions with references.[2][3][8][11][14]

01

Which legal entity would sign the engagement and receive fees today: Geller Biopharm Inc., Pickwick Capital Partners, LLC, or another entity

Historical materials associate Geller Biopharm with Financial West Group, while current materials identify Matthew Geller and Pickwick Capital Partners in the present regulatory context.[2][10][12]
02

What current firm-level registrations, supervisory arrangements, and securities licenses apply

The current Pickwick biography identifies Matthew Geller as a FINRA-registered representative but does not establish a current firm-level registration status for Geller Biopharm Inc.[2]
03

Can the advisor provide three recent completed healthcare transactions with dates, roles, consideration, and references

Publicly identifiable examples include transactions and assignments announced through 2020, while the accessible Pickwick Select Transactions page does not provide Geller Biopharm-specific transaction names, dates, or values in its accessible text.[8][13]

What size transactions and clients does Geller Biopharm Inc focus on?

Geller Biopharm is publicly positioned around healthcare, biotechnology, and biopharmaceutical companies. Its attributed transaction materials also identify pharmaceutical and medical-device companies within its described coverage.[1][3]

  • Geller Biopharm acted as financial advisor on Agenus Inc.’s February 5, 2014 public offering of common stock.
  • Geller Biopharm acted as co-manager on Parnell Pharmaceuticals’ proposed initial public offering announced May 21, 2014.
  • A 2016 SEC-filed transaction document states that a company agreed to pay Geller Biopharm, described there as a healthcare investment-banking division of Financial West Group, a fee in connection with certain contemplated transactions.
  • Pickwick’s official news archive identifies Geller Biopharm’s representation of Amunix in a Merck licensing transaction announced January 3, 2019.
  • The same archive identifies Geller Biopharm’s representation of ViralClear in financing-related work announced April 23 and April 24, 2020, and its exclusive representation of CaroGen for licensing and financing announced March 10, 2020.
[5][6][7][8]

The public record identifies work across public offerings, a proposed initial public offering, licensing, financing-related assignments, mergers and acquisitions, and advisory or consulting engagements.

Pickwick’s current biography states that Geller Biopharm has performed numerous M&A and advisory transactions as a consultant. The accessible Pickwick investment-banking page does not publish Geller Biopharm-specific minimum transaction criteria.[1][2][5][6][8][14]

What does Geller Biopharm Inc publicly disclose about fees, process and engagement terms?

The current Pickwick biography identifies Matthew Geller as a FINRA-registered representative with Pickwick Capital Partners but does not establish a current firm-level registration status for Geller Biopharm Inc.

The accessible Pickwick investment-banking page does not publish Geller Biopharm-specific fee schedules, minimum transaction criteria, or engagement terms. The accessible Pickwick Select Transactions page presents transaction image tiles but does not identify Geller Biopharm-specific transaction names, dates, or values in its accessible text.

The gellerbiopharm.com homepage was not retrievable during the current research pass because the page timed out, so no homepage content was captured from that URL.[2][13][14][15]

Historical SEC-filed materials describe Geller Biopharm as a healthcare investment-banking division of Financial West Group. A FINRA BrokerCheck firm report identifies Financial West Investment Group, Inc., doing business as Financial West Group, and lists Geller Biopharm as a healthcare investment-banking division name used by that firm.

Current Pickwick materials identify Pickwick Capital Partners, LLC as a FINRA and SIPC member and Matthew Geller as a FINRA-registered representative with Pickwick. The current Pickwick biography does not establish a current firm-level registration status for Geller Biopharm Inc.[2][10][11][12]

Public descriptions indicate that Geller Biopharm has undertaken advisory, M&A, licensing, consulting, financing, and capital-raising assignments. The accessible Pickwick investment-banking page does not publish Geller Biopharm-specific engagement terms, fee schedules, or minimum transaction criteria.[1][3][5][6][8][14]

Questions to ask before hiring Geller Biopharm Inc

Which legal entity would sign the engagement and receive fees today: Geller Biopharm Inc., Pickwick Capital Partners, LLC, or another entity?
Historical materials associate Geller Biopharm with Financial West Group, while current materials identify Matthew Geller and Pickwick Capital Partners in the present regulatory context.[2][10][12]
What current firm-level registrations, supervisory arrangements, and securities licenses apply?
The current Pickwick biography identifies Matthew Geller as a FINRA-registered representative but does not establish a current firm-level registration status for Geller Biopharm Inc.[2]
Can the advisor provide three recent completed healthcare transactions with dates, roles, consideration, and references?
Publicly identifiable examples include transactions and assignments announced through 2020, while the accessible Pickwick Select Transactions page does not provide Geller Biopharm-specific transaction names, dates, or values in its accessible text.[8][13]
What are the fee, retainer, success-fee, reimbursement, exclusivity, termination, and tail provisions?
The accessible Pickwick investment-banking page does not publish Geller Biopharm-specific fee schedules or engagement terms.[14]
What buyer, licensing-partner, and capital-source relationships are active for the relevant therapeutic area?
Public descriptions identify licensing, M&A, financing, and capital-raising work. Current relationship coverage for a particular therapeutic area should be confirmed directly.[1][3][8]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Identity / organization record
  3. Identity / organization record
  4. SEC filing / regulatory record
  5. SEC filing / regulatory record
  6. Transaction / portfolio evidence
  7. SEC filing / regulatory record
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. SEC filing / regulatory record
  11. Structure / regulatory context
  12. FINRA regulatory record
  13. Public disclosure information
  14. Public disclosure information
  15. Public disclosure information
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.